{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:30:06Z","timestamp":1783747806359,"version":"3.55.0"},"reference-count":21,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"DOI":"10.1001\/jamaoncol.2020.1250","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T05:20:48Z","timestamp":1589520048000},"page":"e201250","source":"Crossref","is-referenced-by-count":51,"title":["Low-Dose Erlotinib Treatment in Elderly or Frail Patients With <i>EGFR<\/i> Mutation\u2013Positive Non\u2013Small Cell Lung Cancer"],"prefix":"10.1001","volume":"6","author":[{"given":"Shingo","family":"Miyamoto","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Japanese Red Cross Medical Center, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Azuma","sequence":"additional","affiliation":[{"name":"Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenobu","family":"Ishii","sequence":"additional","affiliation":[{"name":"Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Bessho","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Hosokawa","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Fukamatsu","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Okayama Hospital, Okayama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Kunitoh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Japanese Red Cross Medical Center, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen\u2019s Hospital, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Aono","sequence":"additional","affiliation":[{"name":"Respiratory Medicine, Mitsui Memorial Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Nakahara","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Kusaka","sequence":"additional","affiliation":[{"name":"The Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Hosomi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Kasumigaura Medical Center, Tsuchiura, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Iwate Prefectural Central Hospital, Morioka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Itani","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Japanese Red Cross Ise Hospital, Ise, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Hamada","sequence":"additional","affiliation":[{"name":"Division of Molecular Pharmacology, National Cancer Center Research Institute, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Yamada","sequence":"additional","affiliation":[{"name":"Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine and Medical Oncology, Yokohama Municipal Citizen\u2019s Hospital, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"issue":"25","key":"coi200017r1","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non\u2013small-cell lung cancer with mutated EGFR.","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"issue":"27","key":"coi200017r2","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"coi200017r3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer.","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"coi200017r4","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1200\/JCO.2008.18.7658","article-title":"First-line gefitinib for patients with advanced non\u2013small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.","volume":"27","author":"Inoue","year":"2009","journal-title":"J Clin Oncol"},{"issue":"9","key":"coi200017r5","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1097\/JTO.0b013e318260de8b","article-title":"First-line gefitinib in patients aged 75 or older with advanced non\u2013small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.","volume":"7","author":"Maemondo","year":"2012","journal-title":"J Thorac Oncol"},{"issue":"1","key":"coi200017r6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00280-015-2784-x","article-title":"Phase II study of erlotinib in elderly patients with non\u2013small cell lung cancer harboring epidermal growth factor receptor mutations.","volume":"76","author":"Inoue","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"coi200017r7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.lungcan.2018.10.014","article-title":"A phase II study of afatinib treatment for elderly patients with previously untreated advanced non\u2013small-cell lung cancer harboring EGFR mutations.","volume":"126","author":"Imai","year":"2018","journal-title":"Lung Cancer"},{"issue":"22","key":"coi200017r8","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology.","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"coi200017r9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1093\/annonc\/mdu540","article-title":"The prevalence and outcomes of frailty in older cancer patients: a systematic review.","volume":"26","author":"Handforth","year":"2015","journal-title":"Ann Oncol"},{"issue":"17","key":"coi200017r10","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1200\/JCO.2008.20.8983","article-title":"Future of cancer incidence in the United States: burdens upon an aging, changing nation.","volume":"27","author":"Smith","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi200017r11","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Aging and pharmacology.","volume":"80","author":"Vestal","year":"1997","journal-title":"Cancer"},{"issue":"31","key":"coi200017r12","doi-asserted-by":"publisher","first-page":"3575","DOI":"10.1200\/JCO.2017.73.8245","article-title":"Starting dose of sorafenib for the treatment of hepatocellular carcinoma: a retrospective, multi-institutional study.","volume":"35","author":"Reiss","year":"2017","journal-title":"J Clin Oncol"},{"issue":"13","key":"coi200017r13","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/cncr.31357","article-title":"Early results of lower dose dasatinib (50?mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"124","author":"Naqvi","year":"2018","journal-title":"Cancer"},{"issue":"27","key":"coi200017r14","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1200\/JCO.2015.63.4154","article-title":"Randomized phase III study comparing gefitinib with erlotinib in patients with previously treated advanced lung adenocarcinoma: WJOG 5108L.","volume":"34","author":"Urata","year":"2016","journal-title":"J Clin Oncol"},{"issue":"14","key":"coi200017r15","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1016\/j.ejca.2015.06.120","article-title":"A prospective, multicentre phase II trial of low-dose erlotinib in non\u2013small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911.","volume":"51","author":"Yamada","year":"2015","journal-title":"Eur J Cancer"},{"issue":"5","key":"coi200017r16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2217\/pgs.11.176","article-title":"Association of ABCB1 polymorphisms with erlotinib pharmacokinetics and toxicity in Japanese patients with non\u2013small-cell lung cancer.","volume":"13","author":"Hamada","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"11","key":"coi200017r17","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","article-title":"Validation of a combined comorbidity index.","volume":"47","author":"Charlson","year":"1994","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"coi200017r18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"13","key":"coi200017r19","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1200\/JCO.2001.19.13.3267","article-title":"Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.","volume":"19","author":"Hidalgo","year":"2001","journal-title":"J Clin Oncol"},{"issue":"14","key":"coi200017r20","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1200\/JCO.2017.76.4381","article-title":"Prospective international randomized phase II study of low-dose abiraterone with food versus standard dose abiraterone in castration-resistant prostate cancer.","volume":"36","author":"Szmulewitz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"coi200017r21","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/S1470-2045(19)30272-4","article-title":"Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.","volume":"20","author":"Bekaii-Saab","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2765756\/jamaoncology_miyamoto_2020_oi_200017.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T15:02:47Z","timestamp":1594306967000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2765756"}},"subtitle":["A Multicenter Phase 2 Trial"],"short-title":[],"issued":{"date-parts":[[2020,7,9]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2020.1250","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,9]]}}}